Skip to content

Pipeline

Pioneering First-in-class therapies for hematological cancers

Stelexis’ lead pipeline programs address novel targets in hematological cancers with thoughtful clinical development strategies designed to produce rapid proof of concept as monotherapies and in combination. 

Program (Target)

Eganelisib
PI3K-𝛄 Inhibitor
Pre-IND
Clinical Stage

Indication(s)

Intermediate-, High-, Very High Risk-MDS, and AML

Ph1 mono in R/R HR-MDS & AML

  • Clinical proof of efficacy confirmed
  • No Myelosuppression
2H26 Start azacitidine + eganelisib in PI3K-y HIGH patients with
HR-MDS in first-line

Indication(s)

AML and CMML

Investigator-Sponsored Trial
Azacitidine + Eganelisib +/- Venetoclax

Enrolling

Program (Target)

STLX-2012
(IL-1RAP)
Pre-IND
Clinical Stage

Indication(s)

Hidradenitis Suppurativa and Other I&I Indications

Planned: Healthy volunteer study

Program (Target) Indication(s)
Progress (there are 2 phases: Pre-IND, and Clinical Stage)
Eganelisib
PI3K-𝛄 Inhibitor
Intermediate-, High-, Very High Risk-MDS, and AML

Ph1 mono in R/R HR-MDS & AML

  • Clinical proof of efficacy confirmed
  • No Myelosuppression
2H26 Start azacitidine + eganelisib in PI3K-y HIGH patients with
HR-MDS in first-line
AML and CMML

Investigator-Sponsored Trial
Azacitidine + Eganelisib +/- Venetoclax

Enrolling
STLX-2012
(IL-1RAP)
Hidradenitis Suppurativa and Other I&I Indications

Planned: Healthy volunteer study

*AML = acute myeloid leukemia; MDS = myelodysplastic syndrome; CMML = chronic myelomonocytic leukemia; HR = Higher-Risk; R/R = relapsed/refractory